CD274 and gastroesophageal junction adenocarcinoma: Unfortunately, it was recently announced that the phase III JAVELIN Gastric 300 trial (NCT02625623), investigating avelumab as a third-line treatment advanced GC and GEJ adenocarcinoma, unselected for PD-L1 expression, failed to meet its primary endpoint (OS) [86].